Open an account

Definium Therapeutics

DFTX · NASDAQ

$35.09+$2.12 (+6.43%)TodayMarket closed ·
Prev close $32.97

About DFTX

Definium Therapeutics, Inc. operates as clinical stage biopharmaceutical company, which engages in developing novel product candidates to treat brain health disorders. The company is headquartered in New York City, New York and currently employs 105 full-time employees. The company went IPO on 2015-05-04. The firm plans to advance DT1201 ODT toward FDA submissions in the two largest psychiatric markets, generalized anxiety disorder (GAD) and major depressive disorder (MDD). Its late-stage pipeline includes four Phase 3 trials, two each for GAD and MDD, anchored by its lead candidate, DT120 ODT, which has received an FDA Breakthrough Therapy Designation for GAD. In parallel, the Company is engaged in advancing its commercial strategy and operational readiness to support a care model and prepare for the launch of DT120 ODT, if approved and marketed. The company also continues to advance its early-stage pipeline, having dosed the first patient in a Phase 2a study of DT4023 in adults with autism spectrum disorder (ASD).

Employees
105
Headquarters
New York City, New York
Listed
May 4, 2015
Sector
Health Care
Industry
Pharmaceuticals
Website
definiumtx.com

DFTX key statistics

Market cap
4.71B
Price-earnings ratio
0.00
Dividend yield
—
Average volume
2.13M
Volume
1.75M
Open price
$32.99
High today
$35.58
Low today
$32.78
52 Week high
$49.70
52 Week low
$10.46

Definium Therapeutics (DFTX) at a glance

As of Oct 20, 2026, Definium Therapeutics (DFTX) shares are priced at $35.09, giving the company a market cap of 4.71B and a price-to-earnings ratio of 0.00.

Today the stock has traded between $32.78 and $35.58. The current price is 7.1% above the day's low and 1.4% below its high.

Volume so far is 1.75M shares, in line with the average of 2.13M shares a day.

Over the past year Definium Therapeutics has ranged from $10.46 to $49.70, and now sits 63% of the way up that range.

Definium Therapeutics met or beat analyst EPS estimates in 2 of the last 8 quarters. In Q2 FY26 it reported -$1.44 per share against an estimate of -$0.5576.

The average analyst price target is $73.32, 108.9% above the current price, from 16 recent ratings.

Analyst ratings

Latest rating from each analyst over the past 12 months

100%of 16 analyst ratings say Buy
  • Buy100.0%
  • Hold0.0%
  • Sell0.0%
Price target · 19 analystsAvg $73.32
Low
$55.55
Now
$35.09
High
$95.55

DFTX earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 2 of the last 8 quarters, by 16.5% on average.

  1. Q3 FY24: reported -$0.27 per share against an estimate of -$0.2856
  2. Q4 FY24: reported -$0.41 per share against an estimate of -$0.3017
  3. Q1 FY25: reported -$0.27 per share against an estimate of -$0.3727
  4. Q2 FY25: reported -$0.50 per share against an estimate of -$0.3717
  5. Q3 FY25: reported -$0.78 per share against an estimate of -$0.5113
  6. Q4 FY25: reported -$0.50 per share against an estimate of -$0.4974
  7. Q1 FY26: reported -$0.71 per share against an estimate of -$0.502
  8. Q2 FY26: reported -$1.44 per share against an estimate of -$0.5576

DFTX news

  • Press releaseBusiness Wire

    Definium Therapeutics Announces New Employee Inducement Grants

  • Press releaseBusiness Wire

    Definium Therapeutics Announces New Employee Inducement Grants

  • Vandana Singh

    Definium Says Its Anxiety Drug Showed 'Unprecedented Efficacy'

  • Press releaseBusiness Wire

    Definium Therapeutics Announces Positive Topline Results from Phase 3 Panorama Study of DT120 ODT in Generalized Anxiety Disorder

  • Press releaseBusiness Wire

    Definium Therapeutics Announces New Employee Inducement Grants

  • Press releaseBusiness Wire

    Definium Therapeutics to Discuss Topline Results from Phase 3 Panorama Study in Generalized Anxiety Disorder on September 14, 2026

  • Press releaseBusiness Wire

    Definium Therapeutics to Present Topline Data from Phase 3 Emerge and Voyage Trials Across Major Depressive Disorder and Generalized Anxiety Disorder at Psych Congress 2026

  • 'FDA’s Acting Drug, Vaccine Regulators Tapped for Permanent Roles'- Bloomberg

Similar companies

Companies in the same industry as Definium Therapeutics

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.